XIANYANG, China, September 18, 2014 /PRNewswire/ - Biostar Pharmaceuticals, Inc.
(NASDAQ: BSPM) ("Biostar" or the “Company"), a PRC-based manufacturer
and marketer of pharmaceutical and health supplement products in China
for a variety of diseases and conditions, announced today it has filed
PRC national invention and creation patent for the pharmaceutical and
preparation method of its new developed product, Oleanolic Acid
Injection, which designed to treat Hepatitis B and liver cancer. The
application passed the preliminary examination of the PRC State
Intellectual Property Bureau and was accepted for review; the
application acceptance number is 201410182757.7.
The filed patent is for the pharmaceutical and preparation
method developed by the Company’s R&D team, together with the
experts of Shaanxi University of Chinese Medicine after nearly 2 years
of research and development effort. It is one of drug development
efforts by the Company in combating Hepatitis B and liver cancer and is
currently under pharmacological research.
Mr. Ronghua Wang, Chairman of the Company commented: “The
filing and acceptance for review of the invention patent application
indicates that the Company had made considerable progress in developing
its Oleanolic Acid Injection. This promises to establish technical
foundation for the product’s research and development and future
expansion. The Company will continue to increase investment in its
research and development efforts to generate effective drugs for the PRC
markets.”
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly
owned subsidiary and controlled affiliate in China, develops,
manufactures and markets pharmaceutical and health supplement products
for a variety of diseases and conditions. The Company's most popular
product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter
("OTC") medicine for chronic hepatitis B, a disease affecting
approximately 10% of the Chinese population. For more information please
visit:
http://www.biostarpharmaceuticals.com.
Labels: Biostar, China, drugs in development, Oleanolic Acid